Torsemide: Potent Loop Diuretic for Effective Fluid Management
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.43 | $38.70 (0%) | 🛒 Add to cart |
| 120 | $0.39 | $51.60 $46.44 (10%) | 🛒 Add to cart |
| 180 | $0.33 | $77.40 $60.20 (22%) | 🛒 Add to cart |
| 270 | $0.31 | $116.10 $83.42 (28%) | 🛒 Add to cart |
| 360 | $0.29
Best per pill | $154.80 $104.06 (33%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.76 | $45.58 (0%) | 🛒 Add to cart |
| 90 | $0.69 | $68.37 $61.92 (9%) | 🛒 Add to cart |
| 120 | $0.65 | $91.16 $78.26 (14%) | 🛒 Add to cart |
| 180 | $0.62 | $136.74 $110.94 (19%) | 🛒 Add to cart |
| 270 | $0.59 | $205.11 $159.10 (22%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $273.48 $208.12 (24%) | 🛒 Add to cart |
Synonyms | |||
Torsemide is a high-ceiling loop diuretic indicated for the management of edema associated with congestive heart failure, renal disease, and hepatic cirrhosis. It acts on the thick ascending limb of the loop of Henle to inhibit the Na+/K+/2Cl- cotransporter, resulting in profound natriuresis and diuresis. Its predictable pharmacokinetic profile, including high bioavailability and a longer half-life compared to furosemide in some patients, makes it a valuable therapeutic option for clinicians seeking consistent fluid removal. This agent is particularly noted for its reliable absorption and potential additional benefits in certain patient populations.
Features
- Chemical name: 1-isopropyl-3-[(4-m-toluidino-3-pyridyl)sulfonyl]urea
- Standard available strengths: 5 mg, 10 mg, 20 mg, 100 mg tablets
- Mechanism: Selective inhibition of the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle
- Bioavailability: Approximately 80-90%, with minimal effect of food
- Onset of action: Within 60 minutes following oral administration
- Peak effect: 1-2 hours post-dose
- Duration of action: 6-8 hours
- Metabolism: Primarily hepatic via CYP2C9
- Excretion: Approximately 80% renal, 20% fecal
- Pregnancy category: C (risk cannot be ruled out)
Benefits
- Effective fluid removal: Provides potent diuresis, often resulting in significant weight reduction and relief from pulmonary and peripheral edema
- Predictable pharmacokinetics: High and consistent bioavailability reduces interpatient variability in response compared to other loop diuretics
- Potential cardioprotective effects: Some evidence suggests beneficial effects on collagen turnover markers and cardiac remodeling in heart failure patients
- Flexible dosing: Available in multiple strengths allowing for precise titration to individual patient needs
- Convenient once-daily dosing: For many patients, single daily administration provides adequate diuretic control
- Potential renal protective aspects: May offer advantages in patients with renal impairment due to dual hepatic and renal elimination pathways
Common use
Torsemide is primarily prescribed for the treatment of edema associated with congestive heart failure, chronic renal insufficiency, and hepatic cirrhosis. It is also used as monotherapy or in combination with other antihypertensive agents for the management of hypertension. In clinical practice, it is often selected for patients who demonstrate inadequate response to or unpredictable absorption with furosemide. The medication is particularly valuable in heart failure management programs where consistent fluid removal is critical to preventing hospitalizations and maintaining clinical stability.
Dosage and direction
For edema in congestive heart failure: The usual initial dose is 10-20 mg once daily. If diuretic response is insufficient, the dose may be doubled until the desired effect is achieved. Doses above 200 mg have not been studied adequately.
For chronic renal failure: Initial dose of 20 mg once daily, titrated upward according to patient response. Doses up to 100 mg twice daily have been used in severe cases under close medical supervision.
For hepatic cirrhosis: Start with 5-10 mg once daily administered together with an aldosterone antagonist or potassium-sparing diuretic. Dose may be adjusted upward, typically not exceeding 40 mg daily.
For hypertension: Initial dose of 5 mg once daily, which may be increased to 10 mg after 4-6 weeks if blood pressure remains uncontrolled.
Administration should generally occur in the morning to prevent nocturia. Tablets may be taken with or without food. For patients requiring large doses, split dosing (twice daily) may be implemented to maintain more consistent diuretic effect while minimizing peak-trough fluctuations.
Precautions
Patients should be monitored regularly for signs of electrolyte imbalance, particularly hypokalemia, hyponatremia, and hypochloremic alkalosis. Renal function should be assessed periodically, especially in patients with pre-existing renal impairment or those taking nephrotoxic medications. Hepatic function monitoring is advised in patients with liver disease due to potential precipitation of hepatic encephalopathy in susceptible individuals. Ototoxicity, while less common than with other loop diuretics, may occur particularly with rapid intravenous administration or in patients with renal impairment. Patients should be cautioned about potential photosensitivity reactions and advised to use sun protection. Blood glucose should be monitored in diabetic patients, as hyperglycemia may occur.
Contraindications
Torsemide is contraindicated in patients with known hypersensitivity to sulfonamide-derived drugs or any component of the formulation. Anuria unresponsive to a trial dose of loop diuretic represents an absolute contraindication. The drug is contraindicated in patients with hepatic coma or severe electrolyte depletion until these conditions are corrected. It should not be used in patients with documented sulfa allergy, though cross-reactivity between antibacterial sulfonamides and non-antibacterial sulfonamides remains controversial.
Possible side effect
Common adverse reactions (≥2%) include:
- Excessive urination (expected therapeutic effect)
- Headache (5-7%)
- Dizziness (3-5%)
- Asthenia (2-4%)
- Electrolyte depletion (hypokalemia 3-15%, hyponatremia 1-3%)
- Hyperglycemia (1-4%)
- Hyperuricemia (2-5%)
- Increased serum creatinine (1-3%)
Less frequent but serious adverse effects:
- Ototoxicity (tinnitus, hearing loss) - particularly with rapid IV administration or renal impairment
- Severe dehydration and hypovolemia
- Orthostatic hypotension
- Stevens-Johnson syndrome (rare)
- Pancreatitis (rare)
- Thrombocytopenia (rare)
Drug interaction
ACE inhibitors and ARBs: Increased risk of hypotension and renal impairment, particularly in volume-depleted patients.
Digoxin: Diuretic-induced hypokalemia may potentiate digoxin toxicity.
Lithium: Reduced renal clearance of lithium, increasing risk of lithium toxicity.
NSAIDs: May attenuate diuretic and antihypertensive effects and increase risk of renal impairment.
Aminoglycosides: Increased risk of ototoxicity and nephrotoxicity.
Probenecid: Reduces diuretic effect by inhibiting tubular secretion of torsemide.
Corticosteroids: Enhanced potassium wasting.
Other antihypertensives: Additive hypotensive effects.
Sucralfate: May reduce absorption of torsemide; administer at least 2 hours apart.
Chloral hydrate: Case reports suggest potential for sweating, flushing, and instability.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is near the time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed dose. For patients taking once-daily dosing in the morning, if remembered in the afternoon or evening, it is generally advisable to skip the dose to prevent nocturnal diuresis and sleep disruption.
Overdose
Overdose may lead to profound diuresis with water and electrolyte depletion, manifested as hypovolemia, dehydration, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Circulatory collapse, cardiac arrhythmias, and thromboembolic events may occur. Treatment is primarily supportive and symptomatic, consisting of fluid and electrolyte replacement. There is no specific antidote. Hemodialysis does not significantly remove torsemide due to high protein binding. Monitoring should include electrolyte levels, renal function, volume status, and ECG for arrhythmias, particularly in patients with pre-existing cardiac conditions.
Storage
Store at controlled room temperature 20°-25°C (68°-77°F), with excursions permitted between 15°-30°C (59°-86°F). Keep container tightly closed and protect from light and moisture. Dispense in original container. Keep out of reach of children and pets. Do not use if the seal is broken or tablets appear discolored or degraded. Properly discard any unused medication after the expiration date.
Disclaimer
This information is intended for healthcare professionals and should not replace personalized medical advice. Dosage and treatment decisions must be made by qualified healthcare providers based on individual patient characteristics, including renal and hepatic function, electrolyte status, and concomitant medications. Patients should be fully informed of potential benefits and risks and monitored appropriately during therapy. The prescriber should consult full prescribing information for complete details before initiating therapy.
Reviews
Clinical studies: Multiple randomized trials have demonstrated torsemide’s efficacy in fluid management. The TORIC study showed significant mortality benefit compared to furosemide in heart failure patients, though larger confirmatory trials are needed. Meta-analyses suggest potential advantages in hospitalization reduction and quality of life measures.
Expert consensus: Nephrologists and cardiologists frequently note torsemide’s predictable absorption profile as a significant advantage over furosemide, particularly in heart failure management where consistent diuresis is critical. Many specialists reserve it for patients demonstrating suboptimal response to other loop diuretics.
Patient reported outcomes: Many patients report preference over furosemide due to more predictable diuretic pattern and less frequent dosing. Some note improved quality of life due to reduced urgency and frequency of urination compared to shorter-acting alternatives.
Safety profile: Generally well-tolerated with adverse effect profile comparable to other loop diuretics. The potentially lower ototoxicity risk compared to furosemide is noted in some comparative studies, though robust head-to-head trials are limited.